Picture Swiss Biotech Association LSUS Global Village 2025 Basel 650x100px

Product › Details

antibody-drug conjugates (ADC) technology

	Next higher product group	drug development technology
	Status	unspecified existent
	Organisation	Seattle Genetics Inc. (Nasdaq: SGEN)
	Today	Seagen Inc. (Nasdaq: SGEN)
	Group	Pfizer (Group)

Record changed: 2025-03-04

Picture Kenes Exhibitions Biomed Israel 2025 Tel Aviv 650x200px

More documents for antibody-drug conjugates (ADC) technology

[1] Callio Therapeutics. (3/3/25). "Press Release: Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept". Seattle, WA & Singapore....
[2] Kivu Bioscience. (10/28/24). "Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates". San Francisco, CA....
[3] Genmab A/S. (4/3/24). "Press Release: Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio". Copenhagen & Seattle, WA....
[4] BioNTech SE. (1/31/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305". Mainz & Shanghai....
[5] Johnson & Johnson. (1/8/24). "Press Release: Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer". New Brunswick, NJ....
[6] MediLink Therapeutics (Suzhou) Co., Ltd.. (1/2/24). "Press Release: MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to Develop Next-generation Antibody Drug Conjugate in Oncology". Suzhou....
[7] Merck & Co., Inc.. (10/19/23). "Press Release: Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs". Basking Ridge, NJ & Rahway, NJ....
[8] Mablink Bioscience SAS. (10/18/23). "Press Release: Mablink Bioscience Enters an Agreement to be Acquired by Lilly". Lyon....
[9] MediLink Therapeutics (Suzhou) Co., Ltd.. (10/12/23). "Press Release: MediLink Therapeutics Announces Strategic Collaboration and Worldwide License Agreement with BioNTech to develop next-generation anti-cancer antibody-drug conjugate". Suzhou....
[10] Tubulis GmbH. (4/20/23). "Press Release: Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients". Munich....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]